IV/SC Initially 50 u/kg 1-2 min 3 times/wk. Dose can be increased by 25 u/kg in 4-wk period. Maintenance: 25-50 u/kg 2 or 3 times/wk. Patient w/ treatment Hb <6 g/dL Max: 200 u/kg 3 times/wk. Patients w/ CRF not on dialysis Individualized according to severity of anemia or age or 70-150 u/kg/wk for >6 mth.
Hypersensitivity or allergic reactions. Patients w/ HTN (BP may rise or hypertensive encephalopathy may occur during therapy); MI, pulmonary infarction or cerebral embolus, thromboembolism; cerebral bleeding or premature infant w/ cerebral bleeding; ischemic vascular disease; history of seizure, epilepsy; thrombocytosis, chronic hepatic failure. Do not use in patients w/ anemia from blood loss, hematocytopenia & Al intoxication. Treatment should be limited in anemic patients w/ chronic renal failure <10 g/dL of Hb or cancer patients w/ serum erythropoietin <200 mU/mL. Monitor patient's history to forecast shock or other responses. Periodically monitor Hb conc or hematocrit during therapy. Caution should be taken to prevent excessive erythropoiesis. Risk of HTN & hypertensive encephalopathy. Monitor seizure, hyperkalemia, pure red cell aplasia. Carefully monitor the blood circulation in shunt & dialysis kit. In case of Fe deficiency, adequate Fe supplementation should be done. May act as a growth factor for tumor particularly myeloid malignancies. Pregnancy & lactation. Childn. Elderly.
Sign Out
